# Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets

> **NCT06450275** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 32 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dolutegravir 50 MG Film Coated Tablet
- **DRUG:** Tivicay 50mg, film-coated tablets

## Key facts

- **NCT ID:** NCT06450275
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-03
- **Primary completion:** 2024-01-15
- **Final completion:** 2024-03-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450275, "Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06450275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*